Literature DB >> 22733128

CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients.

E M Peñas-Lledó, H D Trejo, P Dorado, A Ortega, H Jung, E Alonso, M E G Naranjo, M López-López, A Llerena.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22733128     DOI： 10.1038/mp.2012.91

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN： 1359-4184            Impact factor:   15.992


× No keyword cloud information.
  13 in total

Review 1.  CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials.

Authors:  Eva M Peñas-Lledó; Adrián Llerena
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

Review 2.  Value of Supportive Care Pharmacogenomics in Oncology Practice.

Authors:  Jai N Patel; Lauren A Wiebe; Henry M Dunnenberger; Howard L McLeod
Journal:  Oncologist       Date:  2018-04-05

3.  Impact of cytochrome P450 genes on suicide attempt and risk.

Authors:  Eva M Peñas-Lledó; M Eugenia G Naranjo; Adrián Llerena
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-03-16       Impact factor: 5.270

Review 4.  Pharmacogenetic research activity in Central America and the Caribbean: a systematic review.

Authors:  Carolina Céspedes-Garro; María-Eugenia G Naranjo; Fernanda Rodrigues-Soares; Adrián LLerena; Jorge Duconge; Lazara K Montané-Jaime; Hilda Roblejo; Humberto Fariñas; María de Los A Campos; Ronald Ramírez; Víctor Serrano; Carmen I Villagrán; Eva M Peñas-LLedó
Journal:  Pharmacogenomics       Date:  2016-09-16       Impact factor: 2.533

5.  High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies.

Authors:  M E G Naranjo; F de Andrés; A Delgado; J Cobaleda; E M Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2016-06-07       Impact factor: 3.550

6.  A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances.

Authors:  E Peñas-Lledó; S Guillaume; M E G Naranjo; A Delgado; I Jaussent; H Blasco-Fontecilla; P Courtet; A LLerena
Journal:  Pharmacogenomics J       Date:  2014-08-12       Impact factor: 3.550

7.  The association between CYP2D6 genotype and switching antipsychotic medication to clozapine.

Authors:  Jochem G Gregoor; Karen van der Weide; Jan van der Weide; Harold J G M van Megen; Antoine C G Egberts; Eibert R Heerdink
Journal:  Eur J Clin Pharmacol       Date:  2013-07-07       Impact factor: 2.953

8.  Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.

Authors:  J K Hicks; K Sangkuhl; J J Swen; V L Ellingrod; D J Müller; K Shimoda; J R Bishop; E D Kharasch; T C Skaar; A Gaedigk; H M Dunnenberger; T E Klein; K E Caudle; J C Stingl
Journal:  Clin Pharmacol Ther       Date:  2017-02-13       Impact factor: 6.875

9.  A one-year follow-up study of treatment-compliant suicide attempt survivors: relationship of CYP2D6-CYP2C19 and polypharmacy with suicide reattempts.

Authors:  Eva M Peñas-Lledó; Sebastien Guillaume; Fernando de Andrés; Ana Cortés-Martínez; Jonathan Dubois; Jean Pierre Kahn; Marion Leboyer; Emilie Olié; Adrián LLerena; Philippe Courtet
Journal:  Transl Psychiatry       Date:  2022-10-18       Impact factor: 7.989

10.  High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina.

Authors:  G Moya; P Dorado; V Ferreiro; M E G Naranjo; E M Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2016-04-12       Impact factor: 3.550
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.